Doxycycline Hyclate
ID: SPE2D2-25-R-0004Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/2007e711319b46bcad84a6ac7f88b5e3/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Doxycycline Hyclate Tablets, specifically 100 MG tablets available in various bottle counts. This procurement aims to establish a national supply source for the Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs, ensuring a reliable supply of this essential pharmaceutical product. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in November 2024. Interested parties can reach out to Courtney Hunter-Stangler at (215) 737-6845 or via email at Courtney.Hunter-Stangler@dla.mil for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates.

    Point(s) of Contact
    Courtney Hunter-Stangler
    (215) 737-6845
    Courtney.Hunter-Stangler@dla.mil
    Jason C. Wray
    (215) 737-0614
    Jason.Wray@dla.mil
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Doxycycline Hyclate
    Currently viewing
    Presolicitation
    Similar Opportunities
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Bicalutamide 50MG tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health programs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted on the DLA Bid Board System and Sam.gov. Interested parties should direct inquiries to Keith Ryales at keith.ryales@dla.mil or call 215-737-9199 for further information.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Lamotrigine
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a presolicitation for a national requirements contract for Norgestimate/Ethinyl Estradiol Tablets. The procurement will include various formulations of these oral tablets, specifically Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and Ethinyl Estradiol/Norgestimate tablets, packaged in 3x28 count packs. This contract is crucial for establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable provision of these essential pharmaceuticals. Interested parties should prepare for the solicitation, projected for November 2024, and may contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for further inquiries.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Azithromycin Suspension Solicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Azithromycin Suspension, as outlined in Solicitation No. SPE2D2-25-R-0001. This Request for Proposal (RFP) seeks various formulations of Azithromycin, emphasizing compliance with federal regulations, including the Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS), to ensure the integrity and quality of pharmaceutical supplies. The procurement is critical for maintaining a reliable supply of essential drugs, promoting fair competition among vendors, and adhering to legal provisions regarding production and subcontracting. Interested vendors must submit their offers electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between October 29 and December 2, 2024. For further inquiries, contact Kahaun Vicks at Kahaun.Vicks@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.